Labs / ADME, DMPK & toxicology

Complement Therapeutics
London, United Kingdom · complementtx.com
On your own
Free. Their own email.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Complement Therapeutics is a clinical-stage biotechnology company developing precision therapies for complement-mediated diseases, with an initial focus on geographic atrophy, an advanced form of dry age-related macular degeneration. It develops AAV-based gene therapy designed to deliver mini-CR1 locally to retinal cells to modulate complement activity in the eye. The company is based in Munich, London, and Stevenage.
They take quote requests by email.
What they offer
Complement-mediated disease therapy development
Develops precision therapies aimed at restoring complement balance in complement-driven diseases.
Ocular gene therapy development
Develops AAV-based gene therapies for local treatment of complement-driven eye disease.
CTx001 development
Advances CTx001, an AAV gene therapy encoding mini-CR1 for geographic atrophy secondary to age-related macular degeneration.
Scientific collaboration and partnerships
Invites scientific collaboration, partnerships, and general enquiries related to its research and development programmes.
What they work on
- Modalities
- Viral vector
- Therapeutic areas
- geographic atrophy, age-related macular degeneration, ophthalmology, complement-mediated diseases
- Sites
- Munich, Germany · London, United Kingdom · Stevenage, United Kingdom
- Address
- 84 Wood Lane London, W12 0BZ United Kingdom Complement Therapeutics Ltd LabG16 Ste
Similar labs. ProtaGene, Aclairo Pharmaceutical Development Group, Inc., Aizant Drug Research Solutions Pvt. Ltd., Antheia
Found in a contract services directory. Listing built from complementtx.com. Work here? Claim this listing.